PMID- 30848017
OWN - NLM
STAT- MEDLINE
DCOM- 20200312
LR  - 20200312
IS  - 1753-0407 (Electronic)
IS  - 1753-0407 (Linking)
VI  - 11
IP  - 10
DP  - 2019 Oct
TI  - Prognosis for residual islet beta-cell secretion function in young patients with 
      newly diagnosed type 1 diabetes.
PG  - 818-825
LID - 10.1111/1753-0407.12912 [doi]
AB  - BACKGROUND: This study investigated possible predictors of residual islet beta-cell 
      function (RBF) in young patients with newly diagnosed type 1 diabetes (T1D). 
      METHODS: After analyzing RBF in 443 patients with T1D according to age at 
      diagnosis and disease duration, 110 were followed-up over 18-60 months. A 
      nomogram was developed by logistic regression to explore factors associated with 
      long-term RBF. RESULTS: Of the 443 T1D patients (mean [+/-SD] age 
      20.28 +/- 5.50 years; mean [+/-SD] diabetes duration 28.5 +/- 14.6 months), RBF was 
      preserved in 64.3%. Independent predictors for poor RBF outcome among the 110 
      patients in the follow-up cohort were age at onset (odds ratio [OR] 0.82; 95% 
      confidence interval [CI] 0.73-0.92; P < 0.001), high-risk human leukocyte antigen 
      (HLA) status (OR 4.73; CI 1.28-17.52; P = 0.020), female sex (OR 3.39; CI 
      1.03-11.22; P = 0.045), and a history of diabetic ketoacidosis (DKA; OR 8.71; CI 
      2.31-32.83; P < 0.001). Baseline glutamic acid decarboxylase (GAD) antibody, 
      family history of diabetes, body mass index, insulin dosage, and C-peptide and 
      HbA1c levels were not associated with poor RBF outcome. Intensive glycemic 
      control after T1D diagnosis may improve RBF within a mean (+/-SD) follow-up of 
      35.1 +/- 13.8 months. The calibration plot for the probability of 2-, 3-, and 
      4-year RBF showed optimal agreement between nomogram-predicted and actual 
      observed probabilities. CONCLUSIONS: Younger age of onset, female sex, higher HLA 
      risk status, and a history of DKA were the main factors predicting long-term poor 
      preserved beta-cell function. Glycemic control could improve RBF during the course 
      of diabetes. The nomogram provides an individualized risk estimate of RBF in 
      patients with newly diagnosed T1D within Chinese Han populations.
CI  - (c) 2019 Ruijin Hospital, Shanghai Jiaotong University School of Medicine and John 
      Wiley & Sons Australia, Ltd.
FAU - Miao, Haitao
AU  - Miao H
AD  - Department of Endocrinology and Metabolic Diseases, Ruijin Hospital, Shanghai 
      Jiao-Tong University, Shanghai, China.
FAU - Zhang, Juanjuan
AU  - Zhang J
AD  - Department of Endocrinology and Metabolic Diseases, Ruijin Hospital, Shanghai 
      Jiao-Tong University, Shanghai, China.
FAU - Gu, Bin
AU  - Gu B
AD  - Department of Endocrinology and Metabolic Diseases, Ruijin Hospital, Shanghai 
      Jiao-Tong University, Shanghai, China.
FAU - Gao, Aibo
AU  - Gao A
AD  - Department of Endocrinology and Metabolic Diseases, Ruijin Hospital, Shanghai 
      Jiao-Tong University, Shanghai, China.
FAU - Hong, Jie
AU  - Hong J
AD  - Department of Endocrinology and Metabolic Diseases, Ruijin Hospital, Shanghai 
      Jiao-Tong University, Shanghai, China.
FAU - Zhang, Yifei
AU  - Zhang Y
AD  - Department of Endocrinology and Metabolic Diseases, Ruijin Hospital, Shanghai 
      Jiao-Tong University, Shanghai, China.
FAU - Gu, Weiqiong
AU  - Gu W
AUID- ORCID: 0000-0002-3296-3384
AD  - Department of Endocrinology and Metabolic Diseases, Ruijin Hospital, Shanghai 
      Jiao-Tong University, Shanghai, China.
LA  - eng
GR  - 81370934/Chinese National Natural Science Foundation/
GR  - 2016YFC1305202/National Key R&D Program of China/
GR  - 20161403/Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant 
      Support/
PT  - Journal Article
DEP - 20190422
PL  - Australia
TA  - J Diabetes
JT  - Journal of diabetes
JID - 101504326
RN  - 0 (Biomarkers)
RN  - 0 (Insulin)
SB  - IM
MH  - Adult
MH  - Biomarkers/*metabolism
MH  - Diabetes Mellitus, Type 1/diagnosis/*physiopathology
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Insulin/*metabolism
MH  - Insulin-Secreting Cells/metabolism/*pathology
MH  - Male
MH  - *Nomograms
MH  - Prognosis
MH  - Young Adult
OTO - NOTNLM
OT  - 1型糖尿病
OT  - HLA class II
OT  - HLA-II类基因
OT  - Nomogram预测模型
OT  - prognostic nomogram
OT  - residual islet beta-cell function
OT  - type 1 diabetes
OT  - 残余胰岛beta细胞功能
EDAT- 2019/03/09 06:00
MHDA- 2020/03/13 06:00
CRDT- 2019/03/09 06:00
PHST- 2018/09/20 00:00 [received]
PHST- 2019/02/27 00:00 [revised]
PHST- 2019/03/05 00:00 [accepted]
PHST- 2019/03/09 06:00 [pubmed]
PHST- 2020/03/13 06:00 [medline]
PHST- 2019/03/09 06:00 [entrez]
AID - 10.1111/1753-0407.12912 [doi]
PST - ppublish
SO  - J Diabetes. 2019 Oct;11(10):818-825. doi: 10.1111/1753-0407.12912. Epub 2019 Apr 
      22.